Insight gaps leave Biopharma vulnerable to patent cliff crisis, warns expert
With unprecedented patent cliffs looming, putting an estimated $200 to $400 billion in annual global sales at risk , senior strategy consultant and Nmblr founder, Janice MacLennan, is issuing a stark warning to biopharma organisations tasked with delivering innovative new therapies to market.
MacLennan cautions that without a radical shift in the way teams approach commercialisation strategy development, systemic insight gaps could leave biopharma organisations vulnerable to the patent cliff crisis; preventing breakthrough science from translating into breakthrough impact for patients, providers, and healthcare systems.
“With patent cliffs of unprecedented scale looming, biosimilars are not just competing with old drugs but they are making it harder for new innovations to cut through. Coupled with increasing innovation competition in key therapeutic areas, including oncology, inflammation, and neurology, it’s never been more critical for biopharma teams to go deeper; to move beyond disconnected data and uncover the insights needed to unlock behaviour change with living commercialisation strategies built around clearly defined and externally grounded value narratives,” explains MacLennan.
After a 30-year career observing the constraints and challenging the siloed status quo of biopharma commercialisation strategy development, MacLennan advocates for a move away from a disconnected, data-rich/insight poor approach. Without this shift, she argues that external market factors, like the pending patent cliff crisis, will leave biopharma organisations vulnerable and threaten innovation.
MacLennan warns: “If teams don’t take action now to break down internal silos, true insight will remain out of reach, strategy by consensus will continue to dominate, and falling victim to market volatility, patent cliffs and increasing competition will become more likely.”
To support biopharma organisations in avoiding this fate, MacLennan has created a new collaborative toolkit for cross-functional, geographically dispersed teams to uncover market truths, challenge assumptions in real time, assess risk and opportunity from the customer perspective, and make insight actionable. Part of the Nmblr tech ecosystem, the new Discover toolkit consists of three core modules: Inspire – to illuminate the patient journey; Pulse – to deepen understanding of how and where to engage stakeholders; and Scout – to keep pace with the evolving competitive landscape.
“Commercialisation strategy too often develops in fragments, with different teams holding different data, priorities and assumptions,” explains MacLennan. “Nmblr’s Discover toolkit changes that dynamic. By bringing insights into a shared, living strategy space, teams can work together, align around what patients actually experience, who genuinely influences decisions, and where the competitive landscape is shifting. When that picture is visible and actionable across functions and geographies, organisations stop second-guessing each other and start building strategies that reflect market reality – not internal consensus.
MacLennan continues: “Discover creates the conditions for teams to question what they think they know, stress-testing their reading of stakeholder needs, pressure-checking their competitive positioning, and identifying where their current thinking may be misaligned with market reality. The result is a strategic foundation that is sharper, more externally anchored, and better equipped to hold up in an increasingly competitive, complex and shifting environment.”
The Discover toolkit is part of Nmblr — the collaborative strategy platform that helps biopharma teams move as one.
Learn more at www.nmblr.co.
This content was provided by Nmblr
Company Details
Latest Content from Nmblr
Insight gaps leave Biopharma vulnerable to patent cliff crisis, warns expert
With unprecedented patent cliffs looming, putting an estimated $200 to $400 billion in annual global sales at risk , senior strategy consultant and Nmblr founder, Janice MacLennan, is issuing a...
Five Predictions That Will Reshape Biopharma Commercialisation in 2026
Every year, we’re met with restructuring, hiring freezes, and portfolio cuts. And every year we tell ourselves the same story. It’s a rough patch. A cycle that will reverse. But...